ClinicalTrials.gg
WithdrawnNCT07133178Updated Dec 31, 2025

A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children

A Phase 3 interventional study of VLA1553 and Control in Chikungunya Virus Infection, sponsored by Valneva Austria GmbH. Withdrawn. Open to participants aged 1 Year to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by Valneva Austria GmbH (part of Valneva) · Phase 3, Interventional, and Prevention

Why this study was withdrawn
No participant recruited; trial initiation postponed to an unspecified future time while Valneva assesses potential pathways to address regulatory requests. Evaluation is ongoing to ensure alignment with regulatory expectations and obligations.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
1 Year to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Chikungunya Fever by Valneva — 2 open to participants now, 5 under way, 1 of them phase 3. Chikungunya Fever · Valneva.

Started
2026
with 3 others
Phase 3
5 of 11
none open now
Registered
7th of 11
by date

Among the 11 studies in Chikungunya Fever by Valneva, this one is one of 4 that started in 2026, is one of 5 in phase 3, and was the 7th registered.

Chikungunya Fever

88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.

Browse Chikungunya Fever studies →

Open to participants now

2 of the 11 studies in Chikungunya Fever by Valneva are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 11 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Chikungunya Fever by Valneva, or all of them as a file.
02

Study summary

VLA1553-322 is a multicenter, prospective, randomized, double-blind, phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix®) for each stratum (age group). At least 3,000 male and female healthy children aged 1 to 11 years will be enrolled and randomized 3:1 to either VLA1553 (n=2,250) or comparator (Nimenrix®) (n=750).

Read the detailed description

This is a multicenter, prospective, randomized, double-blind, Phase 3 clinical trial evaluating VLA1553 in comparison to a comparator (Nimenrix®) in healthy children aged 1 to 11 years after a single vaccination in endemic countries.

The overall trial duration (First Participant In - Last Participant Out) is estimated to be approximately 22 months. Individual participation is approximately 13 months (immunogenicity subset) from ICF signature to trial completion, unless prematurely discontinued.

At least 3,000 male and female healthy children aged 1 to 11 years will be enrolled and randomized 3:1 to either VLA1553 (n=2,250) or comparator (Nimenrix®) (n=750). These children will be screened for evidence of previous CHIKV exposure.

The trial will be conducted in Latin America and / or Southeast Asia to ensure a diverse participant population and broad applicability of results. An independent Data and Safety Monitoring Board (DSMB) will oversee participant safety, review interim data, and provide recommendations on the trial's continuation. Additionally, a Valneva internal Safety Review Committee (SRC) will review safety data according to their pertinent SRC Charter.

The trial is divided into three sequential parts with predefined timepoints: Part A (Day 29, Visit 4), Part B (Month 6, Visit 6) and Part C (Month 12, Visit 7). Analyses for each part will be conducted independently after the last participant completes the respective visit, with Part A analyzed after Day 29, Part B after Month 6, and Part C after Month 12.

03

Conditions studied

  • Chikungunya Virus Infection

Browse trials for

04

Who can participate

Ages eligible
1 Year to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female healthy children aged 7 to 11 years for Stratum A, 3 to 6 years for Stratum B and 1 to 2 years for Stratum C at the time of obtaining participant / assent;
  2. Written informed consent by the participant's parent(s) / Legally Acceptable Representative(s) (LAR(s), according to local requirements, and written informed assent of the participant, if applicable;
  3. Participant is generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests;
  4. Participants in Stratum C (1 to 2 years) must be within the normal WHO growth and weight ranges for their age.
  5. Participant is seropositive for previous CHIKV exposure (i.e. IgM+ / IgG+ or IgM- / IgG+) or seronegative (i.e. IgM- / IgG-);
  6. If participant is of (e.g. after onset of menarche) and if involved in activities that could result in pregnancy:

    1. Female participant has a negative pregnancy test (in accordance with local regulations) at Screening (Visit 0) and Day 1 (Visit 1), respectively;
    2. Female participant has practiced an adequate method of during at least the 30 days before Screening (Visit 0) and during the Screening period;
    3. Female/ male participant agrees to employ adequate birth control measures ) for the first three months post-vaccination (i.e. until Day 85, Visit 5).

Exclusion criteria

Exclusion Criteria:

  1. Participant who is anti-CHIKV IgM+ / IgG- does not qualify for participation in this trial.
  2. Participant is taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or has participated in a clinical trial involving an CHIKV vaccine;
  3. Participant has an acute or recent infection and who is not symptom-free in the week prior to both the Screening visit (Visit 0) and Visit 1;
  4. Participant has received another within 28 days or inactivated / other vaccine within 14 days prior to vaccination in this trial or plans to receive a live virus vaccine within 28 days or inactivated vaccine / other within 14 days after vaccination; Whenever possible, standard of care vaccinations should be planned with the trial VLA1553 administration in mind.
  5. Participant has an ongoing medical history of or currently has acute or progressive, unstable, controlled or uncontrolled clinical condition (e.g., cardiovascular, respiratory, neurologic, psychiatric, or rheumatologic conditions) that poses a risk for participation in the trial, based on the Investigators clinical judgement. Examples include individuals with controlled, poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance with pharmacologic treatment, or presence of high-risk comorbidities (e.g., significant cardiopulmonary disease);
  6. Participant has abnormal findings in any required trial investigations (including medical history, physical examination, and clinical laboratory) considered by the Investigator which pose a risk for participation in the trial based on his / her judgement;
  7. Participant has a history of immune-mediated or clinically relevant arthritis / arthralgia;
  8. The participant, their parent(s) / LAR(s) or siblings have a known , or infection;
  9. Participant has a history of ;
  10. Participant has a known or suspected defect of the immune system that can be expected to influence the immune response to the vaccine, such as participants with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to Visit 1. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent ≥0.05 mg / kg / day within 4 weeks prior to trial entry, radiation therapy or cytotoxic drugs / monoclonal antibodies in the previous 3 years; topical and inhaled are allowed.
  11. Participant has a history of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of VLA1553 or Nimenrix®, or other known including febrile convulsions);
  12. Participant presents with clinical conditions representing severe bleeding disorders and medications interfering with blood clotting;
  13. Participant is pregnant (positive pregnancy test - in accordance with local regulations - at Screening or Visit 1, respectively) or is lactating at the time of enrollment or, for participants involved in activities potentially leading to pregnancy:

    1. female participants on unreliable after onset of menarche
    2. male participant does not agree to employ adequate birth control measures during the first three months:
  14. Participant received blood-derived products (e.g. plasma) within 180 days prior to vaccination in this trial;
  15. Participant has a rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site AE measurement and rating;
  16. Participant has participated in another clinical trial involving an investigational medicinal product (IMP) or device within 30 days prior to vaccination or is scheduled to participate in another clinical trial involving an IMP, or device at any time during this trial;
  17. Participant has any condition that, in the opinion of the Investigator, may compromise the participants well-being, might interfere with evaluation of trial endpoints, or would limit the participant's ability to complete the trial;
  18. Participant / Participant's parent(s) / LAR(s) is / are a member of the team conducting the trial or in a dependent relationship with one of the trial team members. Dependent relationships include close relatives (i.e., children, partner / spouse, siblings, parent(s) / LAR(s) as well as employees of the Investigator or site personnel conducting the trial;
  19. Participant has received the comparator (Nimenrix® or any equivalent meningococcal conjugate vaccine covering serogroups A, C, W-135, and Y) prior to the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    VLA1553

    VLA1553

    Biological: VLA1553

  • Active comparator
    Control

    Nimenrix will be used as Comparator

    Biological: Control

Interventions

  • BiologicalVLA1553

    Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine

  • BiologicalControl

    Single intramuscular vaccination on Day 1 with Nimenrix (Men ACWY vaccine), a conjugate vaccine indicated for the active immunization

06

What researchers measure

Primary outcomes

  1. The proportion of participants with a seroresponse as defined by μPRNT50 for baseline negative participants

    Time frame: 28 days post-vaccination

Secondary outcomes

  1. Immune response as measured by CHIKV-specific neutralizing antibody titers as determined by μPRNT assay

    Time frame: on Day 1, Day 15, Day 29, Day 85, Day 180, and Month 12 (Day 365)

  2. Proportion of participants with seroresponse as determined by μPRNT assay

    Time frame: on Day 15, Day 29, Day 85, Day 180 and Month 12 (Day 365)

  3. Proportion of participants with seroconversion as compared to baseline as determined by μPRNT assay

    Time frame: on Day 15, Day 29, Day 85, Day 180 and Month 12 (Day 365)

  4. Fold increase of CHIKV-specific neutralizing antibody titers determined by μPRNT assay as compared to baseline

    Time frame: on Day 15, Day 29, Day 85, Day 180 and Month 12 (Day 365)

  5. Proportion of participants reaching an at least 4-fold, 8-fold, 16-fold, or 64-fold increase in CHIKV-specific neutralizing antibody titers compared to baseline as measured by μPRNT assay

    Time frame: on Day 15, Day 29, Day 85, Day 180 and Month 12 (Day 365)

  6. Antibody titers, seroresponse, seroconversion and fold increases for CHIKV-specific neutralizing antibodies, determined by μPRNT assay stratified by CHIKV baseline serostatus (based on μPRNT) and age stratum

    Time frame: at Day 15, Day 29, Day 85, Day 180 and Month 12 (Day 365)

  7. Frequency and severity of any Adverse Event (AE), stratified by CHIKV baseline serostatus and age stratum

    Time frame: until Day 29

  8. Frequency and severity of unsolicited Adverse Events (AE), stratified by CHIKV baseline serostatus and age stratum

    Time frame: until Day 180 and Month 12

  9. Frequency and severity of solicited injection site and systemic Adverse Event (AE), stratified by CHIKV baseline serostatus and age stratum

    Time frame: within 14 days post-vaccination

  10. Frequency and relatedness of any Serious Adverse Event (SAE), stratified by CHIKV baseline serostatus and age stratum

    Time frame: during entire trial period

  11. Frequency and severity of any adverse event of special interest (AESI), stratified by CHIKV baseline serostatus and age stratum

    Time frame: starting within 2 to 21 days post-vaccination

  12. Frequency and severity of any late onset adverse event of special interest (AESI), stratified by CHIKV baseline serostatus and age stratum

    Time frame: during the entire trial starting 22 days post-vaccination

  13. Frequency and severity of adverse event of special interest (AESI) (regulatory agency definition), stratified by CHIKV baseline serostatus and age stratum

    Time frame: with an onset within 30 days post-vaccination

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — After trial completion, Valneva may provide access to individual de-identified participant data and related trial documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Trial Report (CTR)) upon request from qualified researchers, and subject to Valneva's review and approval.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2025
First posted
Aug 20, 2025
StartEst.
Feb 6, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Nov 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07133178
Responsible party
Sponsor
First posted
Aug 20, 2025
Start date
Feb 6, 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Valneva Clinical Development
study chair · Valneva Austria GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chikungunya vaccine

Start the discussion